Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Tom Allinder who wrote (57571)	8/2/2000 10:39:41 AM
From: Due Diligence	Respond to of 150070

CCAA: Some block buys this AM. Expecting positive appreciation in stock price when Multi-Million Deals close. In negotiations for last few weeks. Been basing at this level. DD

To: Tom Allinder who wrote (57571)	8/2/2000 10:40:51 AM
From: Tom Allinder	Read Replies (1) \| Respond to of 150070

Rumor... news release coming on ESTG... Big thing with this company: Broad-based clinical trials (scheduled to start June 2000), file with the F.D.A. for approval, commence manufacturing and marketing, and finance future inventory. The Company expects clinicals to take about six months and the F.D.A. to grant approval within six months of filing. The clinical trials are underway... there will be more on this soon... FDA approval: The company seems willing to keep shareholders updated on this. Here is more on it: The ELAST Device(TM) is a patented, non-invasive diagnostic tool designed to accurately diagnose allergies, as well as food and chemical sensitivities immediately and without any of the pain or expense associated with currently employed testing methods. Current allergy testing methods include the oral challenge test as well as blood and skin prick testing. These methods all include the introduction of the potential allergen to the body with concomitant discomfort and risks. In contrast, the ELAST Device(TM) is being designed to test for allergies and sensitivities non-invasively through means of simple exposure, without the introduction into the body of the potential allergen. The ELAST Device(TM) is based upon the clinical observation that the normal flow of electricity in the human body is altered when its immune system is exposed to a substance to which it is sensitive or allergic. The non-invasive nature of the ELAST Device(TM) is possible because the device measures the body's electrical response when it is exposed to an allergen, and through this measurement the ELAST Device(TM) assesses the testing subject's profile of reactions to various substances. "By employing the breakthrough announced today ELAST's scientists now have an alternative non-invasive method of exposing the testing subject to a potential allergen, thereby increasing the opportunities to measure the alteration in the body's electrical response to a sensitivity," stated ELAST Technologies' founder and Chief Scientist Robert D. Milne, M.D. Tom